A ketogenic diet substantially reshapes the human metabolome.


Journal

Clinical nutrition (Edinburgh, Scotland)
ISSN: 1532-1983
Titre abrégé: Clin Nutr
Pays: England
ID NLM: 8309603

Informations de publication

Date de publication:
07 2023
Historique:
received: 21 10 2022
revised: 17 01 2023
accepted: 28 04 2023
medline: 19 6 2023
pubmed: 4 6 2023
entrez: 3 6 2023
Statut: ppublish

Résumé

Western dietary habits (WD) have been shown to promote chronic inflammation, which favors the development of many of today's non-communicable diseases. Recently, ketogenic diets (KD) have emerged as an immune-regulating countermeasure for WD-induced metaflammation. To date, beneficial effects of KD have been solely attributed to the production and metabolism of ketone bodies. Given the drastic change in nutrient composition during KD, it is reasonable to assume that there are widespread changes in the human metabolome also contributing to the impact of KD on human immunity. The current study was conducted to gain insight into the changes of the human metabolic fingerprint associated with KD. This could allow to identify metabolites that may contribute to the overall positive effects on human immunity, but also help to recognize potential health risks of KD. We conducted a prospective nutritional intervention study enrolling 40 healthy volunteers to perform a three-week ad-libitum KD. Prior to the start and at the end of the nutritional intervention serum metabolites were quantified, untargeted mass spectrometric metabolome analyses and urine analyses of the tryptophan pathway were performed. KD led to a marked reduction of insulin (-21.45% ± 6.44%, p = 0.0038) and c-peptide levels (-19.29% ± 5.45%, p = 0.0002) without compromising fasting blood glucose. Serum triglyceride concentration decreased accordingly (-13.67% ± 5.77%, p = 0.0247), whereas cholesterol parameters remained unchanged. LC-MS/MS-based untargeted metabolomic analyses revealed a profound shift of the human metabolism towards mitochondrial fatty acid oxidation, comprising highly elevated levels of free fatty acids and acylcarnitines. The serum amino acid (AA) composition was rearranged with lower abundance of glucogenic AA and an increase of BCAA. Furthermore, an increase of anti-inflammatory fatty acids eicosatetraenoic acid (p < 0.0001) and docosahexaenoic acid (p = 0.0002) was detected. Urine analyses confirmed higher utilization of carnitines, indicated by lower carnitine excretion (-62.61% ± 18.11%, p = 0.0047) and revealed changes to the tryptophan pathway depicting reduced quinolinic acid (-13.46% ± 6.12%, p = 0.0478) and elevated kynurenic acid concentrations (+10.70% ± 4.25%, p = 0.0269). A KD fundamentally changes the human metabolome even after a short period of only three weeks. Besides a rapid metabolic switch to ketone body production and utilization, improved insulin and triglyceride levels and an increase in metabolites that mediate anti-inflammation and mitochondrial protection occurred. Importantly, no metabolic risk factors were identified. Thus, a ketogenic diet could be considered as a safe preventive and therapeutic immunometabolic tool in modern medicine. German Clinical Trials Register; DRKS-ID: DRKS00027992 (www.drks.de).

Sections du résumé

BACKGROUND
Western dietary habits (WD) have been shown to promote chronic inflammation, which favors the development of many of today's non-communicable diseases. Recently, ketogenic diets (KD) have emerged as an immune-regulating countermeasure for WD-induced metaflammation. To date, beneficial effects of KD have been solely attributed to the production and metabolism of ketone bodies. Given the drastic change in nutrient composition during KD, it is reasonable to assume that there are widespread changes in the human metabolome also contributing to the impact of KD on human immunity. The current study was conducted to gain insight into the changes of the human metabolic fingerprint associated with KD. This could allow to identify metabolites that may contribute to the overall positive effects on human immunity, but also help to recognize potential health risks of KD.
METHODS
We conducted a prospective nutritional intervention study enrolling 40 healthy volunteers to perform a three-week ad-libitum KD. Prior to the start and at the end of the nutritional intervention serum metabolites were quantified, untargeted mass spectrometric metabolome analyses and urine analyses of the tryptophan pathway were performed.
RESULTS
KD led to a marked reduction of insulin (-21.45% ± 6.44%, p = 0.0038) and c-peptide levels (-19.29% ± 5.45%, p = 0.0002) without compromising fasting blood glucose. Serum triglyceride concentration decreased accordingly (-13.67% ± 5.77%, p = 0.0247), whereas cholesterol parameters remained unchanged. LC-MS/MS-based untargeted metabolomic analyses revealed a profound shift of the human metabolism towards mitochondrial fatty acid oxidation, comprising highly elevated levels of free fatty acids and acylcarnitines. The serum amino acid (AA) composition was rearranged with lower abundance of glucogenic AA and an increase of BCAA. Furthermore, an increase of anti-inflammatory fatty acids eicosatetraenoic acid (p < 0.0001) and docosahexaenoic acid (p = 0.0002) was detected. Urine analyses confirmed higher utilization of carnitines, indicated by lower carnitine excretion (-62.61% ± 18.11%, p = 0.0047) and revealed changes to the tryptophan pathway depicting reduced quinolinic acid (-13.46% ± 6.12%, p = 0.0478) and elevated kynurenic acid concentrations (+10.70% ± 4.25%, p = 0.0269).
CONCLUSIONS
A KD fundamentally changes the human metabolome even after a short period of only three weeks. Besides a rapid metabolic switch to ketone body production and utilization, improved insulin and triglyceride levels and an increase in metabolites that mediate anti-inflammation and mitochondrial protection occurred. Importantly, no metabolic risk factors were identified. Thus, a ketogenic diet could be considered as a safe preventive and therapeutic immunometabolic tool in modern medicine.
TRIAL REGISTRATION
German Clinical Trials Register; DRKS-ID: DRKS00027992 (www.drks.de).

Identifiants

pubmed: 37270344
pii: S0261-5614(23)00141-3
doi: 10.1016/j.clnu.2023.04.027
pii:
doi:

Substances chimiques

Tryptophan 8DUH1N11BX
Triglycerides 0
Insulin 0
Ketone Bodies 0

Banques de données

DRKS
['DRKS00027992']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1202-1212

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest The authors have no conflicts of interest to declare.

Auteurs

David Effinger (D)

Walter Brendel Centre of Experimental Medicine, Ludwig-Maximilian-University Munich (LMU), Munich, Germany; Department of Anaesthesiology, Research Unit Molecular Medicine, University Hospital, LMU Munich, Munich, Germany. Electronic address: david.effinger@med.uni-muenchen.de.

Simon Hirschberger (S)

Walter Brendel Centre of Experimental Medicine, Ludwig-Maximilian-University Munich (LMU), Munich, Germany; Department of Anaesthesiology, Research Unit Molecular Medicine, University Hospital, LMU Munich, Munich, Germany. Electronic address: simon.hirschberger@med.uni-muenchen.de.

Polina Yoncheva (P)

Department of Anaesthesiology, Research Unit Molecular Medicine, University Hospital, LMU Munich, Munich, Germany. Electronic address: polina.yoncheva@med.uni-muenchen.de.

Annika Schmid (A)

Walter Brendel Centre of Experimental Medicine, Ludwig-Maximilian-University Munich (LMU), Munich, Germany; Department of Anaesthesiology, Research Unit Molecular Medicine, University Hospital, LMU Munich, Munich, Germany. Electronic address: annika.schmid@med.uni-muenchen.de.

Till Heine (T)

Biovis Diagnostik MVZ GmbH, Limburg, Germany. Electronic address: till.heine@biovis.de.

Patrick Newels (P)

Biovis Diagnostik MVZ GmbH, Limburg, Germany. Electronic address: Patrick.Newels@biovis.de.

Burkhard Schütz (B)

Biovis Diagnostik MVZ GmbH, Limburg, Germany. Electronic address: burkhard.schuetz@biovis.de.

Chen Meng (C)

Bavarian Center for Biomolecular Mass Spectrometry, TUM School of Life Sciences, Technical University of Munich, Freising, Germany. Electronic address: chen.meng@tum.de.

Michael Gigl (M)

Bavarian Center for Biomolecular Mass Spectrometry, TUM School of Life Sciences, Technical University of Munich, Freising, Germany. Electronic address: michael.gigl@tum.de.

Karin Kleigrewe (K)

Bavarian Center for Biomolecular Mass Spectrometry, TUM School of Life Sciences, Technical University of Munich, Freising, Germany. Electronic address: karin.kleigrewe@tum.de.

Lesca-Miriam Holdt (LM)

Institute of Laboratory Medicine, University Hospital, LMU Munich, Munich, Germany. Electronic address: lesca.holdt@med.uni-muenchen.de.

Daniel Teupser (D)

Institute of Laboratory Medicine, University Hospital, LMU Munich, Munich, Germany. Electronic address: daniel.teupser@med.uni-muenchen.de.

Simone Kreth (S)

Walter Brendel Centre of Experimental Medicine, Ludwig-Maximilian-University Munich (LMU), Munich, Germany; Department of Anaesthesiology, Research Unit Molecular Medicine, University Hospital, LMU Munich, Munich, Germany. Electronic address: simone.kreth@med.uni-muenchen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH